And How PursueCare Can Help
Recently, the FDA has pushed for 7-OH Mitragynine, a high-potency form of Kratom sold in head shops, to be classified as a Schedule I substance. If approved, possession of this substance will become illegal, and many individuals dependent on it may face severe opioid- like withdrawal symptoms.
At PursueCare, we are proactively preparing for this potential surge in patients needing support. Our medical and psychiatric teams are developing specific protocols to safely manage withdrawal, guide treatment planning, and ensure patients have access to the care they need. We are committed to training our providers on the latest research about 7-OH Mitragynine, including its effects,
dosage risks, and toxicity. This means when you or a loved one seeks help, you can trust that our team is equipped with the knowledge and tools to provide safe, effective care.
If you or someone you know is using Kratom or 7-OH Mitragynine and are concerned about withdrawal or dependence, PursueCare is here to help. Our experts can create a personalized treatment plan to support recovery, manage symptoms, and provide ongoing guidance throughout the process.
Your health and safety are our top priority. Don’t wait—reach out to PursueCare to learn more about safe withdrawal options and how we can support your journey to recovery.
About PursueCare’s Medical Director
Dr. Kirby leverages his expertise in addiction medicine to deliver comprehensive, patient-centered care through a digital medical home model. He is the President of the Tennessee Society of Addiction Medicine and an expert in population health policy, healthcare economics, evidence-based outcomes-oriented addiction medicine, and human behavior. He is dual board-certified in addiction medicine from the American Board of Preventive Medicine and family medicine from the American Board of Family Medicine.